Wolfe starts J&J at Outperform, sees growth drivers as ‘best-in-class’
Wolfe Research analyst Alexandria Hammond initiated coverage of Johnson & Johnson (JNJ) with an Outperform rating and $190 price target ...
99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows
Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.